» Articles » PMID: 33127456

Prior Presumed Coronavirus Infection Reduces COVID-19 Risk: A Cohort Study

Overview
Journal J Infect
Date 2020 Oct 31
PMID 33127456
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immunological cross-reactivity between common cold coronaviruses (CCC) and SARS-CoV-2 might account for the reduced incidence of COVID-19 in children. Evidence to support speculation includes in vitro evidence for humoral and cellular cross-reactivity with SARS-CoV-2 in specimens obtained before the pandemic started.

Method: We used retrospective health insurance enrollment records, claims, and laboratory results to assemble a cohort of 869,236 insured individuals who had a PCR test for SARS-CoV-2. We estimated the effects of having clinical encounters for various diagnostic categories in the year preceding the study period on the risk of a positive test result.

Findings: After adjusting for age, gender and care seeking behavior, we identified that individuals with diagnoses for common cold symptoms, including acute sinusitis, bronchitis, or pharyngitis in the preceding year had a lower risk of testing positive for SARS-CoV-2 (OR=0.76, 95%CI=0.75, 0.77). No reduction in the odds of a positive test for SARS-CoV-2 was seen in individuals under 18 years. The reduction in odds in adults remained stable for four years but was strongest in those with recent common cold symptoms.

Interpretation: While this study cannot attribute this association to cross-immunity resulting from a prior CCC infection, it is one potential explanation. Regardless of the cause, the reduction in the odds of being infected by SARS-CoV-2 among those with a recent diagnosis of common cold symptoms may have a role in shifting future COVD-19 infection patterns from endemic to episodic.

Citing Articles

High transmission of endemic human coronaviruses before and during the COVID-19 pandemic in adolescents in Cebu, Philippines.

Joseph J, Ylade M, Daag J, Aogo R, Crisostomo M, Mpingabo P BMC Infect Dis. 2024; 24(1):1042.

PMID: 39333882 PMC: 11430261. DOI: 10.1186/s12879-024-09672-8.


Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients.

Lidenge S, Yalcin D, Bennett S, Ngalamika O, Kweyamba B, Mwita C Viruses. 2024; 16(3).

PMID: 38543814 PMC: 10975915. DOI: 10.3390/v16030448.


Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.

Abela I, Schwarzmuller M, Ulyte A, Radtke T, Haile S, Ammann P mBio. 2024; 15(2):e0272223.

PMID: 38270455 PMC: 10865973. DOI: 10.1128/mbio.02722-23.


A Sequent of Gram-Negative Co-Infectome-Induced Acute Respiratory Distress Syndrome Are Potentially Subtle Aggravators Associated to the SARS-CoV-2 Evolution of Virulence.

Said K, Alsolami A, Alshammari K, Alshammari F, Alhallabi S, Alafnan S Diagnostics (Basel). 2024; 14(1).

PMID: 38201429 PMC: 10802668. DOI: 10.3390/diagnostics14010120.


Immune imprinting and next-generation coronavirus vaccines.

Huang C, Vishwanath S, Carnell G, Chan A, Heeney J Nat Microbiol. 2023; 8(11):1971-1985.

PMID: 37932355 DOI: 10.1038/s41564-023-01505-9.


References
1.
Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

2.
Altmann D, Boyton R . SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020; 5(49). DOI: 10.1126/sciimmunol.abd6160. View

3.
Simon A, Hollander G, McMichael A . Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015; 282(1821):20143085. PMC: 4707740. DOI: 10.1098/rspb.2014.3085. View

4.
Meyer B, Drosten C, Muller M . Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014; 194:175-83. PMC: 7114385. DOI: 10.1016/j.virusres.2014.03.018. View

5.
Lv H, Wu N, Tsang O, Yuan M, Perera R, Leung W . Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020; 31(9):107725. PMC: 7231734. DOI: 10.1016/j.celrep.2020.107725. View